This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Remdesivir 100 IV Infusion as a lyophilized powder
Baricitinib oral tablet form
Tocilizumab IV Infusion
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
RECRUITINGTime to Clinical Improvement (TTCI)
Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of \</= 2 Maintained for 24 Hours.
Time frame: Following randomization 30 days
Mortality Rate
Mortality Rate on Days during hospitalization
Time frame: Following randomization 30 days.
Duration of ICU stay
Duration of ICU Stay in days.
Time frame: Following randomization 30 days.
Duration total hospital stay
Duration of hospital stay in days.
Time frame: Following randomization 30 days.
Rate of daily Supplemental Oxygen Use
Rate of daily Supplemental Oxygen Use by the patient
Time frame: Following randomization 30 days.
Time to Clinical Failure
Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)
Time frame: Following randomization 30 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.